American Academy of Pediatrics [AAP] Subcommittee on Attention-Deficit Hyperactivity Disorder and Committee on Quality Improvement (2001) Clinical Practice Guideline: Treatment of the School-Aged Child with Attention-Deficit/Hyperactivity Disorder. Pediatrics, 108, 1033-1044.

has been cited by the following article:

• TITLE: Is the Treatment of Attention Deficit Hyperactivity Disorder a New Cause of Cataract?

  AUTHORS: Mujdat Karabulut, Sinem Karabulut, Tolga Kocatürk, Seyhan Bahar Ozkan

  KEYWORDS: Attention Deficit Hyperactivity Disorder, Methylphenidate, Cataract

  JOURNAL NAME: Open Journal of Ophthalmology, Vol.8 No.1, February 5, 2018

  ABSTRACT: Attention deficit hyperactivity disorder (ADHD) is the most common behavioral disorder of childhood and it has 5% prevalence among children worldwide [1]. In the treatment of ADHD stimulant medications are recommended as the first choice of pharmacotherapy [2]. Methylphenidate-HCl is a sympathomimetic amine derivative pharmacological agent; and it is widely used in the treatment of ADHD. Although there are some articles showing that oral methylphenidate increases the risk of glaucoma [3], to the best of our knowledge, there is only one case report that indicates a possible relation of methylphenidate treatment and cataract formation [4].